Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis (MS). Abata obtained FDA clearance for a first-in-human study of ABA-101 in patients with MS in July.
Many patients with peripheral nerve diseases do not have a sufficient regenerative response because of genetic inheritance, infections or chronic disease, leading them to lifelong pain and disability.
Researchers from Fate Therapeutics Inc. presented preclinical data for the multiplexed-engineered, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy, FT-522, as a potential therapeutic against autoimmune diseases.
Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.
Killer immunoglobulin-like receptor (KIR)-chimeric antigen receptor (CAR) T-cell therapies have previously demonstrated superior performance and functional persistence in solid tumor models, and the mesothelin-specific KIR-CAR T cells, Synkir-110, are now being evaluated in phase I trials by Verismo Therapeutics Inc.
α-Fetoprotein (AFP) is a tumor-associated antigen and an ideal target for T-cell receptor T-cell (TCR-T) therapy. While the safety of AFP-targeting TCR-T products has been previously demonstrated in early clinical trials, the efficacy of these cell therapies is still modest, warranting further research.
Replay Holdings LLC and The University of Texas MD Anderson Cancer Center report that the FDA has cleared the IND application for PRAME TCR/IL-15 NK (SY-307), an engineered T-cell receptor natural killer (TCR-NK) cell therapy for relapsed/refractory myeloid malignancies.
The U.S. FDA has cleared Tr1x Inc.’s IND application for TRX-103 for the prevention of graft-vs.-host disease (GVHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT).
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation.
RSS
